LabCompass

Zemin Wang

Medicine · Indiana University

OpenAlex ORCID
PARP inhibition in cancer therapyMitochondrial Function and PathologyCarcinogens and Genotoxicity AssessmentCancer Immunotherapy and BiomarkersCatalytic C–H Functionalization Methods

Publications

167

Citations

4,750

Est. group size

—

Recurring co-author estimate

Active years

37

Publishing since 1989

Research summary
AI-generated

The publication record associated with this name spans several distinct fields, including cancer drug development (such as inhibitors of the PARP-1 and SHP2 enzymes), probiotics and gut microbiome research, and synthetic organic chemistry (catalytic reactions on alkenes and fluorinated compounds). The work appears to cover both laboratory studies and some clinical or patient-focused topics. Note that the diversity of subjects suggests this record may combine more than one author sharing the same name.

Cancer therapeutics and enzyme inhibitorsProbiotics and gut microbiomeSynthetic and catalytic chemistryColorectal cancer and immunotherapyNeurological and inflammatory disease

Publication activity has fluctuated over the past decade, with a notable peak in 2023 followed by a decline in the most recent years.

Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026

Publication cadence
Publications per year over the last 10 years — averaging 9.0/year recently
2017: 10 publications172018: 14 publications182019: 16 publications192020: 8 publications202021: 9 publications212022: 6 publications222023: 24 publications24232024: 9 publications242025: 6 publications2526
Recent publications
Publishes in
  • Toxicology Letters×4
  • Toxicology×3
  • Green Chemistry×3
  • PLoS ONE×3
  • PubMed×3

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 11, 2026.

Claim or correct this profile